FrancophonIA/ELRC3.0 huggingface dataset:
English: Uncommon side effects (may affect up to 1 in 100 people): - Convulsions (fits) - Speech disorders - Slow heart rate
Croatian: Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba): - konvulzije (napadaji) - poremećaji govora - usporen srčani ritam
English: Antiarrhythmics inducing torsades de pointes (class Ia, Ic, III antiarrhythmics):
Croatian: Antiaritmici koji izazivaju torsades de pointes (antiaritmici skupine Ia, Ic, III):
English: Before starting mexiletine treatment, detailed and careful cardiac evaluation (ECG, 24-48-hour Holtermonitoring and echocardiography) should be carried out in all patients in order to determine the cardiac tolerability of mexiletine.
Croatian: Prije početka terapije meksiletinom, treba provesti detaljnu i pomnu kardijalnu procjenu (EKG, 2448 sati praćenja Holterom i ehokardiografija) kod svih bolesnika, kako bi se utvrdila kardijalna podnošljivost meksiletina.
English: o In patients with cardiac abnormalities, and in patients prone to such abnormalities, a detailed cardiac evaluation (including ECG) should be carried out before and after any dose increase.
Croatian: o kod bolesnika s abnormalnostima srca i kod bolesnika koji imaju sklonosti k takvim abnormalnostima, mora se provesti detaljna procjena srca (uključujući EKG) prije i poslije svakog povećanja doze.
English: 1 Clinical Study Report refers to 200 mg dose which is the amount of mexiletine hydrochloride (corresponding to 166.62mg mexiletine base)
Croatian: Izvještaj iz kliničkog ispitivanja odnosi se na dozu od 200 mg što je količina meksiletinklorida (koja odgovara 166,62 mg baze meksiletina)
English: In a clinical study, 51% of the mexiletine dose was excreted via the kidney at a urinary pH of 5, compared to 10% at normal pH. Changes in urinary pH are not expected to affect efficacy or safety.
Croatian: U kliničkom ispitivanju, 51 % doze meksiletina izlučeno je putem bubrega uz pH mokraće od 5, u usporedbi sa 10 % pri normalnom pH.
English: CYP2D6 polymorphism may affect mexiletine pharmacokinetics (see section 5.2).
Croatian: Polimorfizam CYP2D6 može utjecati na farmakokinetiku meksiletina (vidjeti dio 5.2).
English: Capsule content
Croatian: Sastav kapsule
English: • medicines for heart problems (lidocaine, tocainide, propranolol, esmolol, metoprolol, atenolol, carvedilol, bisoprolol, nebivolol, verapamil, diltiazem),
Croatian: • lijekovi za srčane tegobe (lidokain, tokainid, propranolol, esmolol, metoprolol, atenolol, karvedilol, bisoprolol, nebivolol, verapamil, diltiazem),
English: Clinical Myotonia Scale - Severity Global Score Number of subjects
Croatian: Ljestvica kliničke miotonije - globalni rezultat intenziteta Broj ispitanika
English: • Prompts to enter the contact details of the patient, the treating physician, and Namuscla treatment starting date;
Croatian: • Upute da treba unijeti kontakt podatke bolesnika, liječnika koji ga liječi i datum početka liječenja lijekom Namuscla;
English: Contact your doctor if you take more than the recommended dose of Namuscla.
Croatian: Ako uzmete više lijeka Namuscla nego što ste trebali Obratite se liječniku ako uzmete više od preporučene doze lijeka Namuscla.
English: No dosage adjustment is considered necessary in patients with mild or moderate renal impairment.
Croatian: Smatra se da nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem funkcije bubrega.
English: CYP2D6 polymorphism affects mexiletine pharmacokinetics.
Croatian: Polimorfizam CYP2D6 utječe na farmakokinetiku meksiletina.
English: Mexiletine is a potent inhibitor of CYP1A2; therefore, co-administration of mexiletine with medicinal products metabolised by CYP1A2 (such as theophylline, caffeine, lidocaine or tizanidine) may be associated with elevations in plasma concentrations of the concomitant medicine that could increase or prolong the therapeutic efficacy and/or the adverse reactions, especially if mexiletine is coadministered with CYP1A2 substrates with narrow therapeutic window, e.g. theophylline and tizanidine.
Croatian: Meksiletin je snažan inhibitor CYP1A2; stoga se istodobna primjena meksiletina s lijekovima koji se metaboliziraju putem CYP1A2 (poput teofilina, kofeina, lidokaina ili tizanidina) može povezati s povišenjem koncentracija istodobno primjenjivanih lijekova u plazmi, što bi moglo povećati ili produljiti terapijsku djelotvornost i/ili nuspojave, naročito ako se meksiletin daje istodobno sa supstratima CYP1A2 s uskim terapijskim indeksom, npr. teofilinom i tizanidinom.
English: Rare: hepatic function abnormal
Croatian: Rijetko: poremećaj jetrene funkcije
English: Namuscla 167 mg capsules mexiletine
Croatian: Namuscla 167 mg kapsule meksiletin
English: • Co-administration with medicinal products with narrow therapeutic index (see section 4.5).
Croatian: • Istodobna primjena s lijekovima uskog terapijskog indeksa (vidjeti dio 4.5).
English: Ethnicity
Croatian: Etnička skupina
English: Tell your doctor or pharmacist if you are taking any of the following since these medicines may affect or be affected by Namuscla:
Croatian: Recite svojem liječniku ili ljekarniku ako uzimate bilo što od navedenog jer ti lijekovi mogu utjecati na lijek Namuscla ili lijek Namuscla može utjecati na njih:
English: Very rare: drug reaction with eosinophilia and systemic symptoms Not known: lupus-like syndrome, dermatitis exfoliative, Stevens-Johnson syndrome Psychiatric disorders
Croatian: Nepoznato: sindrom nalik lupusu, eksfolijativni dermatitis, Stevens-Johnsonov sindrom Psihijatrijski poremećaji
English: Mexiletine passes into human milk.
Croatian: Meksiletin se izlučuje u majčino mlijeko čovjeka.
English: Namuscla capsules are Swedish orange hard shell gelatin capsules (20 mm) filled with white powder.
Croatian: Namuscla su ružičasto-tamnocrveno obojene tvrde želatinske kapsule (veličina 20 mm) s bijelim praškom.
English: Mexiletine should be used with caution in patients with mild or moderate hepatic impairment.
Croatian: Meksiletin treba oprezno primjenjivati u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre.
English: Do not take Namuscla with certain medicines for treating heart rhythm disorders (quinidine, procainamide, disopyramide, ajmaline, encainide, flecainide, propafenone, moricizine, amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant).
Croatian: Nemojte uzimati lijek Namuscla s određenim lijekovima za liječenje poremećaja srčanog ritma (kinidin, prokainamid, dizopiramid, ajmalin, enkainid, flekainid, propafenon, moricizin, amiodaron, sotalol, ibutilid, dofetilid, dronedaron, vernakalant).
English: Common: tachycardia
Croatian: Često: tahikardija
English: • Information about the risk of cardiac arrhythmias in patients using Namuscla;
Croatian: • Podatke o riziku od srčanih aritmija u bolesnika koji primaju lijeka Namuscla;
English: Very rare: drug-induced liver injury, liver disorder, hepatitis Skin and subcutaneous tissue disorders Common: acne
Croatian: Vrlo rijetko: oštećenje jetre uzrokovano lijekovima, poremećaj jetre, hepatitis Poremećaji kože i potkožnog tkiva
English: Clinical Global Impression (CGI) Efficacy index Number of subjects
Croatian: Clinical Global Impression, CGI)
English: Common: flushing, hypotension
Croatian: Često: navale crvenila, hipotenzija
English: The patients were randomized according to a cross-over design to a sequence including the 2 following treatments: a) mexiletine, started at 167 mg/day and titrated by increments of 167 mg every 3 days to reach a maximum dose of 500 mg/day in 1 week or b) placebo.
Croatian: meksiletin, s početnom dozom od 167 mg/dan i titriran u koracima od 167 mg svaka 3 dana do postizanja najviše doze od 500 mg/dan za 1 tjedan ili b) placebo.
English: Mean (SD) absolute change from baseline Effect of treatment (Wilcoxon signed-rank test)
Croatian: Učinak liječenja (Wilcoxonov rang test sa znakom)
English: Co-administration of mexiletine and other classes of antiarrhythmics (class Ib: lidocaine, phenytoin, tocainide; class II: propranolol, esmolol, timolol, metoprolol, atenolol, carvedilol, bisoprolol, nebivolol; class IV: verapamil, diltiazem) is not recommended, unless exceptionally, because of the increased risk of adverse cardiac reactions (see section 4.4).
Croatian: Istodobna primjena meksiletina s antiaritmicima ostalih skupina (skupina Ib: lidokain, fenitoin, tokainid; skupina II: propranolol, esmolol, timolol, metoprolol, atenolol, karvedilol, bisoprolol, nebivolol; skupina IV: verapamil, diltiazem) se ne preporuča, osim iznimno, zbog povećanog rizika od srčanih nuspojava (vidjeti dio 4.4).
English: Patients who are CYP2D6 poor metabolisers may exhibit higher mexiletine blood levels (see section 5.2).
Croatian: Bolesnici koji su spori metabolizatori enzima CYP2D6 mogu imati više razine meksiletina u krvi (vidjeti dio 5.2).
English: Median absolute change from baseline Effect of treatment (linear mixed model)
Croatian: Medijan apsolutne promjene u odnosu na početnu točku Učinak liječenja (linearni miješani model)
English: Each capsule contains mexiletine hydrochloride corresponding to 166.62 mg mexiletine .
Croatian: Jedna kapsula sadrži meksiletin hidroklorid koji odgovara 166,62 mg meksiletina.
English: Mexiletine pharmacokinetics are characterised by significantly lower total and renal clearance resulting in prolonged elimination half-life, higher exposure, and lower volume of distribution in poor metabolisers compared to extensive metabolisers.
Croatian: Farmakokinetiku meksiletina obilježava značajno snižen ukupni i bubrežni klirens kod sporih metabolizatora u usporedbi s brzim metabolizatorima, što za posljedicu ima produljeni poluvijek eliminacije, veću izloženost i manji volumen distribucije.
English: Not known: hallucinations, confusional state Nervous system disorders
Croatian: Nepoznato: halucinacije, stanje smetenosti
English: Fatigue, confusion, blurred vision may occur following administration of mexiletine (see section 4.8).
Croatian: Nakon primjene meksiletina može se pojaviti umor, smetenost, zamućen vid (vidjeti dio 4.8).
English: Other medicines and Namuscla
Croatian: Drugi lijekovi i Namuscla
English: Co-administration of mexiletine with a hepatic enzyme inducer (CYP1A2 inducer: omeprazole; CYP2D6 inducer: phenytoin, rifampicin) may increase the clearance and elimination rate of mexiletine due to an increased hepatic metabolism, resulting in decreased plasmatic concentrations and half-life of mexiletine.
Croatian: Istodobna primjena meksiletina s induktorom jetrenih enzima (induktor CYP1A2: omeprazol; induktor CYP2D6: fenitoin, rifampicin) može povećati klirens i brzinu eliminacije meksiletina zbog povećanja jetrenog metabolizma, uzrokujući sniženja koncentracija u plazmi i skraćivanje poluvijeka meksiletina.
English: Mexiletine should not be used in patients with severe hepatic impairment (see section 4.4).
Croatian: Meksiletin se ne smije koristiti u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.4).
English: More than 50% Up to 2%
Croatian: Više od 50 %
English: Namuscla is a medicine that contains the active substance mexiletine.
Croatian: Namuscla je lijek koji sadrži djelatnu tvar meksiletin.
English: Co-administration of mexiletine with a hepatic enzyme inhibitor (CYP1A2 inhibitor: ciprofloxacin, fluvoxamine, propafenone; CYP2D6 inhibitor: propafenone, quinidine) significantly increases mexiletine exposure and thus the associated risk of adverse reactions to mexiletine.
Croatian: Istodobna primjena meksiletina s inhibitorima jetrenih enzima (inhibitor CYP1A2: ciprofloksacin, fluvoksamin, propafenon; inhibitor CYP2D6: propafenon, kinidin) značajno povećava izloženost meksiletinu i sam time povezane rizike od nuspojava meksiletina.
English: o The risk of decreased Namuscla clearance in patients with hepatic impairment (advising patients to inform their HCP if they have any underlying hepatic disorder);
Croatian: o Rizicima od smanjenja klirensa lijeka Namuscla kod bolesnika s oštećenjem jetre (savjetujući bolesnike da odmah kontaktiraju svog liječnika ako imaju neku vrstu oštećenja jetre);
English: Median VAS absolute change from baseline Percentage of Patients with an Absolute VAS Change from Baseline ≥ 50 mm at Day 18 Effect of treatment (Mixed Effect Linear Model)
Croatian: Medijan apsolutne promjene VAS-a u odnosu na početnu točku Postotak bolesnika s apsolutnom promjenom VAS-a u odnosu na početnu vrijednost ≥ 50 mm do 18. dana
English: Poor and extensive CYP2D6 metabolisers
Croatian: Spori i brzi metabolizatori enzima CYP2D6
English: Common: nausea
Croatian: Često: mučnina
English: The experience with mexiletine in patients with severe hepatic impairment is limited.
Croatian: Iskustvo s meksiletinom u bolesnika s teško oštećenom funkcijom bubrega je ograničeno.
English: Each hard capsule contains mexiletine hydrochloride corresponding to 166.62 mg of mexiletine
Croatian: Jedna tvrda kapsula sadrži meksiletinhidroklorid koji odgovara 166,62 mg meksiletina.
English: Co-administration of mexiletine and antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) increases the risk of potentially lethal torsades de pointes.
Croatian: Istodobna primjena meksiletina i antiaritmika koji izazivaju torsades de pointes (skupina Ia: kinidin, prokainamid, dizopiramid, ajmalin; skupina Ic: enkainid, flekainid, propafenon, moricizin; skupina III: amiodaron, sotalol, ibutilid, dofetilid, dronedaron, vernakalant) povećava rizik od potencijalno smrtonosne aritmije torsades de pointes.
English: Each hard capsule contains: - mexiletine hydrochloride corresponding to 166.62 mg of mexiletine (active substance) - Other ingredients (maize starch, colloidal anhydrous silica, magnesium stearate, gelatin, iron oxide [E 172], titanium dioxide [E 171]).
Croatian: Jedna tvrda kapsula sadrži: - meksiletin hidroklorid koji odgovara 166,62 mg meksiletina (djelatne tvari) - Ostali sastojci (kukuruzni škrob, koloidni bezvodni silicijev dioksid, magnezijev stearat,
English: Ultra-rapid metabolisers(UM)
Croatian: Vrlo brzi metabolizatori
English: Oral use.
Croatian: Način primjene Peroralno.
English: o certain antibiotics (ciprofloxacin, rifampicin), o certain antidepressants (fluvoxamine), o tizanidine (used to relax the muscles), o metformin (used against diabetes) o omeprazole (to treat stomach ulcer and gastric acid reflux).
Croatian: • neke druge lijekove o timolol za liječenje visokog pritiska u oku (glaukom), o određene antibiotike (ciprofloksacin, rifampicin), o određene antidepresive (fluvoksamin), o tizanidin (za opuštanje mišića), o metformin (za dijabetes) o omeprazol (za liječenje čira na želucu i refluksa želučane kiseline).
English: CYP1A2 & CYP2D6 inhibitors
Croatian: Inhibitori CYP1A2 i CYP2D6
English: • In patients with cardiac abnormalities, and in patients prone to such abnormalities, detailed cardiac evaluation, including ECG, should be carried out before and after any dose increase.
Croatian: • U bolesnika s kardijalnim anomalijama i u bolesnika koji su im skloni, prije i nakon svakog povećanja doze treba obaviti detaljnu kardijalnu procjenu, uključujući EKG.
English: Namuscla 167 mg hard capsules mexiletine
Croatian: Namuscla 167 mg tvrde kapsule meksiletin
English: • Co-administration with medicinal products inducing torsades de pointes (see section 4.5)
Croatian: • Istodobna primjena s lijekovima koji izazivaju torsades de pointes (vidjeti dio 4.5)
English: It is, therefore, recommended to reduce caffeine intake during treatment with mexiletine.
Croatian: Stoga se tijekom terapije meksiletinom preporuča smanjiti unos kofeina.
English: Not known: leukopenia, thrombocytopenia Immune system disorders
Croatian: Nepoznato: leukopenija, trombocitopenija
English: Holter-monitoring and echocardiography are recommended at least annually, or more frequently, if considered necessary, as part of routine cardiac assessment.
Croatian: Kao dio rutinske procjene, preporučuje se nadzor Holterom i ehokardiografijom barem jednom godišnje ili češće ako se to smatra potrebnim.
English: Namuscla 167 mg hard capsules
Croatian: Namuscla 167 mg tvrde kapsule
English: Lupin Europe GmbH Hanauer Landstraße 139-143, 60314 Frankfurt am Main Germany
Croatian: Lupin Europe GmbH Hanauer Landstraße 139-143, 60314 Frankfurt am Main Njemačka
English: During maintenance treatment, detailed cardiac evaluation, including ECG, 24-48 hour Holtermonitoring and echocardiography, is recommended at least annually, or more frequently if considered necessary as part of routine cardiac assessment.
Croatian: Tijekom terapije održavanja, najmanje jednom godišnje ili po potrebi češće u sklopu uobičajene kardijalne procjene, preporuča se detaljna kardijalna procjena uključujući EKG, 24-48-satno praćenje Holterom i ehokardiografija.
English: Hormosan Pharma GmbH Hanauer Landstraße 139-143, 60314 Frankfurt am Main Germany
Croatian: Hormosan Pharma GmbH Hanauer Landstraße 139-143, 60314 Frankfurt am Main Njemačka
English: Mean (SD) value at Baseline Mean (SD) value at Day 18
Croatian: Srednja vrijednost (SD) u početnoj točki Srednja vrijednost (SD) 18. Dan
English: • Throughout treatment with Namuscla: o In patients without cardiac abnormalities, an electrocardiogram (ECG) monitoring should be performed periodically (every 2 years or more frequently, if considered necessary);
Croatian: o kod bolesnika bez abnormalnosti srca, potreban je periodični nadzor EKG-om (svake 2 godine ili češće ako se smatra potrebnim).
English: CYP1A2 & CYP2D6 inducers
Croatian: Induktori CYP1A2 i CYP2D6
English: Therefore, mexiletine should not be used in this patient population (see section 4.2).
Croatian: Zato se meksiletin ne smije koristiti u ovoj populaciji bolesnika (vidjeti dio 4.2).
English: Intermediate metabolisers (IM)
Croatian: Srednji metabolizatori
English: • Reporting of adverse reactions in patients using Namuscla.
Croatian: • Izvještavanje o nuspojavama kod bolesnika koji primaju lijek Namuscla.
English: Smoking and Namuscla
Croatian: Pušenje i lijek Namuscla
English: - Pulmonary fibrosis (disease of the lung) - Diarrhoea - Vomiting - Injury of the oesophagus (food pipe)
Croatian: - navale vrućine - fibroza pluća (plućna bolest) - proljev - povraćanje - ozljeda jednjaka
English: General disorders and administration site conditions Common: fatigue, asthenia, chest discomfort, malaise
Croatian: Opći poremećaji i reakcije na mjestu primjene Često: umor, astenija, osjećaj neugode u prsima, malaksalost
English: Therefore, the use of mexiletine is not recommended in this patient population (see section 4.2).
Croatian: Zato se primjena meksiletina ne preporuča za ovu populaciju bolesnika (vidjeti dio 4.2).
English: Therefore, the use of mexiletine is not recommended in this patient population (see section 4.4).
Croatian: Zato se primjena meksiletina ne preporuča za ovu populaciju bolesnika (vidjeti dio 4.4).
English: How to take Namuscla
Croatian: Kako uzimati lijek Namuscla
English: Median VAS value at Baseline Median VAS value at Day 18
Croatian: Medijan VAS-a u početnoj točki Medijan VAS-a 18. dan
English: Common: headache, paraesthesia, vision blurred Uncommon: seizure, speech disorders
Croatian: Često: glavobolja, parestezija, zamućen vid
English: Overdose management
Croatian: Zbrinjavanje predoziranja
English: Before starting treatment with Namuscla, you will have tests to check how well your heart is working, including ECG (Electrocardiogram).
Croatian: Vaše srce, uključujući i EKG (elektrokardiogram).
English: Not known: diarrhoea, vomiting, oesophageal ulcers and perforation Hepatobiliary disorders
Croatian: Nepoznato: proljev, povraćanje, čirevi i perforacija jednjaka Poremećaji jetre i žuči
English: Heart function
Croatian: Rad srca
English: If you take more Namuscla than you should
Croatian: Ako ste zaboravili uzeti lijek Namuscla
English: Thus, the carcinogenic risk is unknown.
Croatian: Stoga, karcinogeni rizik nije poznat.
English: <1/100), and not known: cannot be estimated from the available data.
Croatian: <1/100) i nepoznato: ne može se procijeniti iz dostupnih podataka.
English: Repeat steps 1 through 8.
Croatian: Ponovite korake od 1 do 8.
English: For each injection, follow steps 4-10.
Croatian: Za primjenu svake injekcije slijedite korake 4-10.
English: Treatment in this group can therefore not be recommended.
Croatian: Zbog toga se za tu skupinu liječenje ne može preporučiti.
English: No overall differences in safety or effectiveness were observed between elderly and younger patients.
Croatian: Općenito nisu bile opažene razlike u sigurnosti i učinkovitosti između starijih i mlađih bolesnika.
English: The physician educational programme should contain the following key elements:
Croatian: Edukacijski program za liječnike treba sadržavati sljedeće ključne elemente:
English: The reduction of the curve achieved will vary between individuals.
Croatian: Postignuto smanjenje zakrivljenosti razlikovat će se među pojedincima.
English: Patients were however followed up to 36 weeks.
Croatian: bolesnici su bili praćeni do 36 tjedana.
English: The majority of the skin lacerations occurred on the manipulation day.
Croatian: Većina laceracija kože nastala je na dan manipulacije.
English: Altogether 30 female partners participated in the study.
Croatian: U ispitivanju je sudjelovalo ukupno 30 partnerica.
English: In Studies 1 and 2, the co-primary endpoints were:
Croatian: Ispitivanjima 1 i 2 dodatni primarni ciljevi bili su:
English: Long-term efficacy and safety
Croatian: Dugoročna djelotvornost i sigurnost
English: If you receive more Xiapex than you should
Croatian: Ako primite više Xiapexa nego što ste trebali
English: Emergency medication for treatment of potential allergic reactions should be available.
Croatian: Trebaju biti dostupni lijekovi za hitno liječenje mogućih alergijskih reakcija.
English: **Note: 22 subjects were excluded from this analysis.
Croatian: **Napomena: 22 ispitanika bila su isključena iz ove analize.
English: • sudden loss of the ability to maintain an erection
Croatian: • iznenadan gubitak mogućnosti zadržavanja erekcije
English: Hold pressure for 30 seconds then release.
Croatian: Zadržite pritisak tijekom 30 sekundi, a zatim pustite.
English: Bending your penis should not cause any pain or discomfort.
Croatian: Savijanje penisa ne bi trebalo uzrokovati nikakvu bol ni nelagodu.
English: As this medicine is administered to you by your doctor it is very unlikely that you will be given an incorrect dose.
Croatian: Budući da će Vam ovaj lijek davati liječnik, najvjerojatnije nećete dobiti neispravnu dozu.
English: The two classes of collagenases have similar but complementary substrate specificity.
Croatian: Te dvije klase kolagenaza imaju sličnu, ali komplementarnu supstratnu specifičnost.
English: No formal studies on elimination have been performed.
Croatian: Nisu provedena uobičajena ispitivanja eliminacije.
English: Total ROM (°)
Croatian: Ukupni ROM (°)
English: Referenceb Year 2 Year 3 Year 4 Year 5
Croatian: Referentna vrijednostb 2. godina 3. godina 4. godina 5. godina
English: • unpleasant taste
Croatian: • neugodan okus
English: Patients should be instructed to consult a doctor immediately if they experience any of these signs or symptoms.
Croatian: Bolesnike treba uputiti da se odmah jave liječniku ako osjete bilo koji od ovih znakova ili simptoma.
English: This is particularly important for cords situated at the PIP joint of the fifth finger.
Croatian: To je osobito važno kod tračaka koji se nalaze na PIP zglobu petog prsta ruke.
English: • Your doctor will tell you when you can resume sexual activity after each treatment cycle.
Croatian: • Vaš liječnik će Vam reći kada možete nastaviti sa seksualnim aktivnostima nakon svakog ciklusa liječenja.
English: Finger extension procedure
Croatian: Postupak ekstenzije prsta
English: Greater patient satisfaction was correlated with improved range of motion (r=0.51, p<0.001).
Croatian: Veće zadovoljstvo bolesnika koreliralo je s poboljšanim rasponom pokreta (r=0,51, p<0,001).